GlassScriptPhysician profile
Leonard C Kinland
NPI 1760465470
$1,586.25
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $593.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $384.34 | 2019-2020 | |
| Novo Nordisk INC | $248.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.14 | 2019-2020 | |
| Amgen INC. | $122.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $102.09 | 2019-2020 | |
| Allergan, INC. | $89.39 | 2020 | |
| Pfizer INC. | $71.29 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $67.65 | 2019-2020 | |
| Eisai INC. | $44.51 | 2020 | |
| Sanofi-Aventis U.S. LLC | $42.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.21 | 2019 | |
| Sanofi Pasteur INC. | $26.93 | 2019 | |
| Esperion Therapeutics, INC. | $24.84 | 2020 | |
| Amarin Pharma, INC. | $19.02 | 2020 | |
| Genentech USA, INC. | $17.42 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $14.48 | 2020 | |
| Lilly USA, LLC | $13.78 | 2019 | |
| Astellas Pharma US INC | $13.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.30 | 2019 | |
| Shire North American Group INC | $12.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Kinland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.